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Vitexin as an active ingredient in passion flower with potential as an agent for
nicotine cessation: vitexin antagonism of the expression of nicotine locomotor
sensitization in rats
Samantha Bedell , Jacob Wells , Qinfeng Liu and Chris Breivogel
Department of Pharmaceutical Sciences, Campbell University College of Pharmacy & Health Sciences, Buies Creek, NC, USA
ABSTRACT
Context: Nicotine, a bioactive component of tobacco, is highly addictive. Numerous therapies have been
developed for smoking cessation, and all have met with limited success. Our laboratory has previously
shown that an extract of Passiflora incarnata Linn. (Passifloraceae) antagonized the expression of nicotine
locomotor sensitization in rats.
Objective: This study examined the ability of vitexin, a flavonoid found in P. incarnata, to ameliorate the
signs of nicotine sensitization in rats.
Materials and methods: Male Wistar rats were administered 0.4mg/kg nicotine or vehicle (n¼ 16–18 per
group) once a day for four consecutive days. Nicotine administration produces sensitization of locomotor
activity. On the fifth day, locomotor activity was monitored as rats from each treatment group were
administered either 30 or 60mg/kg vitexin or its vehicle (n¼ 4–6 per group) 30min before a challenge
dose of 0.4mg/kg nicotine.
Results: The challenge dose of nicotine resulted in locomotor activity in rats sensitized to nicotine for
4 days that was approximately twice that measured in rats treated with vehicle during the sensitization
phase. Rats sensitized to nicotine and then treated with 60mg/kg vitexin prior to the nicotine challenge
exhibited a level of locomotor activity equivalent to the vehicle-treated controls.
Discussion: Vitexin antagonized the expression of nicotine locomotor sensitization in rats as the whole
extract did in the previous study.
Conclusion: Vitexin should be examined in future studies to evaluate its potential for treating nicotine
addiction in humans.
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Tobacco is the single greatest cause of preventable disease and
premature death in the United States today (Moeller and Sun
2010). Nicotine, the psychoactive ingredient, is both excitatory
and addictive, which account for its stimulating, yet calming
effects (Wadgave and Nagesh 2016). The compound binds to
central nicotinic acetylcholine receptors causing release of the
neurotransmitter dopamine in the mesolimbic area, the corpus
striatum and the frontal cortex (Benowitz 1996). An increase in
dopamine levels in the nucleus accumbens has been shown to be
related to the addictive properties of nicotine (Dani and De Biasi
2001). No existing cessation pharmacotherapy including bupro-
pion, varenicline or nicotine replacement is effective for more
than about one-third of patients (Cahill et al. 2014).
Preparations of passion flower [Passiflora incarnata Linn.
(Passifloraceae)] have been used in traditional and herbal medi-
cines to treat anxiety, insomnia and seizures, but controlled clin-
ical studies of passion flower extract for these indications are
limited (Werneke et al. 2006). Passion flower extract has been
examined in double-blind studies and shown to treat generalized
anxiety disorder similar to oxazepram (Akhondzadeh et al.
2001), to help patients through opiate withdrawal (Akhondzadeh
et al. 2001), and to alleviate pre-surgical anxiety (Movafegh et al.
2008). In laboratory rodents, passion flower extract or single
chemical constituents of passion flower have been shown to be
sedative and anxiolytic (Soulimani et al. 1997; Zanoli et al. 2000;
Krenn 2002) or anticonvulsant (Nassiri-Asl et al. 2007).
Moreover, several studies in laboratory rodents have demon-
strated that whole extracts or an undisclosed benzoflavone moi-
ety from passion flower are anxiolytic, antitussive and
aphrodisiac (Dhawan et al. 2001, 2002). The same investigators
(Dhawan et al. 2004) also showed that the benzoflavone com-
pound, when given together with the addictive agent during the
development of dependence, reduced the symptoms of antagon-
ist-precipitated withdrawal to morphine, alcohol, nicotine, diaze-
pam and D9-tetrahydrocannabinol.
Previous studies have demonstrated that an acute injection of
nicotine to rats results in increased locomotion, and daily injec-
tions result in locomotor sensitization (Ksir et al. 1987; DiFranza
and Wellman 2007; Li et al. 2008). This sensitization is believed
to play an essential role in the development of addiction (Kayir
et al. 2009). Screening for antagonism of the expression of nico-
tine locomotor sensitization is a validated method for identifying
CONTACT Chris Breivogel breivogel@campbell.edu Department of Pharmaceutical Sciences, Campbell University College of Pharmacy & Health Sciences, PO
Box 1090, Buies Creek, NC 27506, USA.
*Present Address: Department of Obstetrics and Gynecology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada.
 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
PHARMACEUTICAL BIOLOGY
2019, VOL. 57, NO. 1, 8–12
https://doi.org/10.1080/13880209.2018.1561725
agents that may promote smoking cessation in humans (Kayir
et al. 2009). A previous study by our laboratory showed that an
extract of passion flower antagonized the expression of nicotine
locomotor sensitization in rats (Breivogel and Jamerson 2012).
The present study hypothesizes that vitexin is the component in
the passion flower extract responsible for this activity.
Materials and methods
Solid-phase extraction (SPE) procedure for purifying passion
flower extract
A 1mL C18 SPE cartridge was pre-washed with 5mL methanol fol-
lowed by 5mL of 0.1% formic acid in H2O. The commercial pas-
sion flower extract (0.3mL; Nature’s Answer, Batch No: 132777)
was diluted (10) with deionized H2O and filtered through a
0.45mm membrane before loading onto an SPE cartridge. The SPE
was washed with 5mL 0.1% formic acid in water, and then eluted
with 2mL 50:50 0.1% formic acid in water/methanol. The elution
fraction was collected and analyzed using LC-MS.
HPLC-mass spectrometry of passion flower extract
An Agilent 1260 HPLC coupled to an Agilent 6540B QTOF was
used. An Agilent extended LC C18 column, 5 cm  2.1mm,
1.7 mm, was used. Gradient elution was performed with 95%/5%
water, 0.1% formic acid:acetonitrile, 0.1% formic acid to 75%
water, 0.1% formic acid: 25% acetonitrile, 0.1% formic acid from
0–16min, then back to 5% acetonitrile, 0.1% formic acid from
16.1 to 19min at a flow rate of 0.4mL/min. Samples or stand-
ards were injected at 5mL. The QTOF MS was equipped with a
dual JetStream ESI probe at positive mode to provide a continu-
ous injection of API-TOF Mass Reference (Agilent, Santa Clara,
CA). It was tuned prior to HPLC-MS analysis to ensure mass
error <10 ppm, and continuously calibrated with the reference to
maintain mass accuracy during HPLC-MS analysis. The QTOF
was run with the following settings: gas temperature 300 C; dry-
ing gas flow rate 12 L/min; nebulizer pressure 35 psig; sheath gas
temperature 325 C; sheath gas flow rate 10 L/min; Vcap 4 kV;
fragmentor 135V; skimmer 65V; OCT RF Vapp 750V; mass
scan range m/z 100–1000. High accuracy QTOF MS data were
analyzed using MassHunter Qualitative Analysis B.06.00 soft-
ware. Compound identification was processed by extracting MS
ions with intensity above 20,000 counts and comparing with a
user-defined database of reported plant flavonoids in literature
for mass match with a mass defect tolerance of 0.05Da.
Drug treatment of rats
All animal work was approved by the Campbell University
Institutional Animal Care and Use Committee (IACUC). Male
Wistar rats, shipped from the Charles River facility in
Morrisville, NC and housed in the Campbell University Animal
facility, were provided with food and water ad libitum and kept
on a 12 h light/dark cycle at approximately 21 C for 2–3weeks
before beginning any treatments. For all experiments, rats were
45–65 days old and between 148 and 260 g. Prior to the treat-
ments specified in each protocol below, each rat was drug-naïve.
Injections of nicotine tartrate or its vehicle (water) were injected
subcutaneously (s.c.) at 0.4mg/kg nicotine base (Sigma Aldrich,
St. Louis, MO) and 2mL/kg. Intraperitoneal (i.p.) injections of
30 or 60mg/kg vitexin (Cayman Chemical Company, Ann
Arbor, MI; Item 15116, Batch: 0500575) or its vehicle (5%
DMSO, 5% Tween-80, 90% saline) were given at 3 or 6mL/kg,
respectively.
Determination of time to habituation and time to peak
effect of nicotine
To determine time to habituation, untreated rats were placed in
separate 44.5 cm 33 cm 38 cm polypropylene spontaneous
activity chambers (Sterilite Corporation, Townsend, MA) for
40min while their locomotor activity was recorded using the
Limelight video tracking system (ActiMetrics, Wilmette, IL).
After 40min, rats were given injections (s.c.) of either vehicle
(water) or 0.4mg/kg nicotine, and were placed back into the
activity chambers where their activity was recorded for another
60min (n¼ 7–18).
Determination of the effect of vitexin on nicotine
sensitization
The protocol and data analysis was very similar to that previously
published with the exception of the intervention agent (vitexin)
(Breivogel and Jamerson 2012). A total of 32 drug-naïve rats were
injected s.c. with the pretreatment of either 0.4mg/kg nicotine or
vehicle (water) once per day for four consecutive days at approxi-
mately 9:00 am. On the fifth day (test day), the rats (4 at a time)
were first put in the spontaneous activity chambers for 30min to
permit habituation. Then each rat was given an i.p. injection of
the intervention, vitexin, at 30 or 60mg/kg or vehicle (5% DMSO,
5% Tween-80, 90% saline) and were then placed back in chambers
for another 30min. At that time, every rat received the challenge
dose of 0.4mg/kg nicotine s.c. and activity was recorded for
another 60min. This produced six treatment groups with the
names referring to the 4-day pretreatment and challenge day
intervention (n in each group): vehicle–vehicle (6), vehicle–30mg/
kg vitexin (4), vehicle–60mg/kg vitexin (8), nicotine–vehicle (6),
nicotine–30mg/kg vitexin (4) and nicotine–60mg/kg vitexin (6).
Determination of the effect of 60mg/kg vitexin alone on
locomotor activity
Rats were given 60mg/kg vitexin or vehicle (i.p.) and were
returned to their home cages for 30min. Rats were then placed
in the spontaneous activity chambers and their activity was
recorded for 30min (n¼ 4 per treatment).
Data analysis
For all experiments, average velocity in cm/s was calculated for
each rat over every 5min interval by averaging the velocities at
each second as provided by Limelight. Figures show the time at
the end of each 5-min interval. For all experiments, 2-way
ANOVA (treatment time) with an a of 0.05 was used to deter-
mine significant differences between treatment groups and
Tukey’s multiple comparisons test identified the time points at
which these differences between groups occurred.
Results
The passion flower extract that was previously shown to antag-
onize the expression of nicotine locomotor sensitization
(Breivogel and Jamerson 2012) was shown to contain a number
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of flavonoids. The most prevalent were isovitexin, vitexin 20-O-
b-D-glucoside (hereafter ‘vitexin-glucoside’) and isovitexin 20-O-
b-D-glucoside (hereafter ‘isovitexin-glucoside’). Smaller amounts
of orientin and isomers, apiin and isomers and luteolin were also
detected (Table 1). In vitro screening using agonists for a variety
of receptors showed that isovitexin and vitexin-glucoside partially
or completely blocked stimulation of [35S]GTPcS binding by the
serotonin 5-HT4 receptor agonist, cisapride and vitexin blocked
dopamine D2 receptor activation by cabergoline (unpublished
observations from our laboratory).
The purpose of the first rat experiment was to confirm the
length of time it would take for rats to habituate to the activity
chambers, and the time course of the locomotor effects of nico-
tine treatment (Figure 1). The locomotor activity of the
untreated rats was initially high for the first 5min (average vel-
ocity of 2.4 cm/s) but steadily subsided to approximately 0.6 cm/s
after 30min and remained at that level or lower over the remain-
ing 30min. After the subsequent vehicle treatment, locomotor
activity remained low with velocities ranging between 0.2 and
0.4 cm/s for the entire 60min period. During the first 15min
after injection of 0.4mg/kg s.c. nicotine, rats exhibited signifi-
cantly greater locomotor activity than vehicle, with values rang-
ing between 1.5 and 2.1 cm/s.
To assess nicotine sensitization and whether vitexin could
antagonize it, rats were given either 0.4mg/kg nicotine or vehicle
once per day for four consecutive days. On the fifth day, loco-
motor activity was determined during each of the three phases
(Figure 2): habituation for 30min (Figure 2, top panel), interven-
tion of vitexin (30 or 60mg/kg) or vehicle for 30min (Figure 2,
middle panel), and following the challenge dose of nicotine to
assess sensitization and antagonism for 60min (Figure 2, bottom
panel). There were no significant differences between any of the
six groups during the first two phases, however, differences were
seen during the first 10min of the third phase. There were no
differences between any of the rats pretreated with vehicle on
days 1–4, regardless of treatment with vitexin or its vehicle on
day 5, and an increase in activity following the nicotine challenge
on day 5 demonstrated the acute stimulatory effect of nicotine.
Rats treated with nicotine on days 1–4, but not with the inter-
vention of vitexin, showed sensitization to nicotine as evidenced
by significantly greater average activity over the first 5min
(p< 0.0001) compared to those that were given vehicle on days
1–4 and vehicle as the intervention (average velocities of 4.0 cm/s
and 1.5 cm/s, respectively). The activity at 5 and 10min of the
nicotine-sensitized rats that received the pretreatment with
30mg/kg vitexin was not different from the nicotine-sensitized
rats that had the vehicle pretreatment, but was different than
rats not sensitized to nicotine (p< 0.01 versus vehicle–vehicle
group and p< 0.05 versus the vehicle–30mg/kg vitexin group).
However, the activity of the nicotine-sensitized rats that received
the pretreatment with 60mg/kg vitexin (nicotine–60mg/kg
vitexin) was significantly lower (p< 0.05) than the activity of the
nicotine-sensitized rats that had the vehicle intervention (nicoti-
ne–vehicle), but not significantly different from any of the un-
sensitized groups.
It was necessary to confirm that the 60mg/kg dose of vitexin
that antagonized the expression of nicotine locomotor sensitiza-
tion did not have a nonspecific effect on locomotor activity in
non-habituated rats (Figure 3). To that end, activity was assessed
after vitexin administration without being allowed to habituate
to the activity chambers, but after a delay of 30min to match the
period between the injection of the intervention agent, vitexin
and the challenge dose of nicotine in the previous experiments.
Rats showed no differences in locomotor activity between vitexin
at 60mg/kg and vehicle (5% DMSO, 5% Tween-80, 90% saline).
Discussion
In previous studies, passion flower extract demonstrated the abil-
ity to attenuate the expression of nicotine locomotor sensitization
in rats (Breivogel and Jamerson 2012). Although no vitexin was
found in the extract, it is likely that some vitexin-glucoside
would be deglycosylated in vivo to vitexin (Nemeth et al. 2003;
Hostetler et al. 2017). Since dopamine D2 receptors are more
likely to be involved in the addictive effects of a drug than
Table 1. Results of HPLC-MS analysis of passion flower extract.
Compound Peak area m/z Retention time (min) Approximated amount in 5 mL SPE extract
Isovitexin 55,700,000 433.102 5.02 550 ng
Vitexin-glucoside or isovitexin-glucoside 10,600,000 595.1519 0.85 260 ng
15,400,000 595.1522 1.85
Total: 2.60E7
Orientin or isomer 5,500,000 1.31 100 ng
4,800,000 1.54
Total 1.03E7
Apiin or isomer 1,330,000 565.1567 0.95 36 ng
2,320,000 565.1566 1.83
Total: 3.65E6
Luteolin 387,000 287.041 10.85 1.3 ng
Figure 1. Time to habituation (left) and time course of the acute locomotor
effect of nicotine or vehicle (right). To determine time needed to habituate, rats
were placed in the spontaneous activity chamber and their activity recorded for
40min (n¼ 18). At the end of 40min, rats were injected s.c. with either the
vehicle water (n¼ 7) or 0.4mg/kg nicotine (n¼ 11) and placed back in the
chamber for 60min. Data shown are mean± SEM for average velocity over each
5-min period. p< 0.05, p< 0.01, p< 0.001 for nicotine versus vehicle by
2-way ANOVA (time vs. treatment) followed by Tukey’s multiple compari-
sons test.
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serotonin 5-HT4 receptors, vitexin was considered the flavonoid
in the passion flower extract most likely to be responsible for the
antagonism of the expression of nicotine locomotor sensitization
observed previously. Thus, vitexin was selected for the behavioral
experiments of this study.
The results from the present study indicated that 30min was
sufficient for the rats to decrease their spontaneous exploratory
behavior, in agreement with previous results (Breivogel and
Jamerson 2012). After the habituated rats were treated with nico-
tine, their locomotor activity increased to a significantly greater
degree than those treated with vehicle. This supports the conclu-
sion that the rats were given enough time to habituate and that
the dose of nicotine used produced a measurable and statistically
significant increase in locomotor activity.
The main goal of the study was to determine if vitexin antag-
onizes the expression of nicotine locomotor sensitization. Prior
to the nicotine challenge dose, nicotine treatments alone did not
affect the locomotor activity or habituation time of the rats
(Figure 2, top panel). Furthermore, neither dose of vitexin
altered the activity of the rats prior to the nicotine challenge,
regardless of pretreatment on the first four days (Figure 2, mid-
dle panel). These results indicate that the activity of the rats was
not affected by the nicotine pretreatments on days 1–4 or by the
vitexin at either dose in the first 30min after administration.
Locomotor sensitization to nicotine was seen after four daily
injections of nicotine (Figure 2, bottom panel). This was shown
by the greater increase in activity in the nicotine–vehicle group
compared to the vehicle–vehicle group (or any group that
received the 4 day vehicle pretreatment). In the final (antagon-
ism) phase of the experiment, there was no difference between
the nicotine–30mg/kg vitexin group and the nicotine–vehicle
group, but there was a significant difference between the nicoti-
ne–30mg/kg vitexin and vehicle–vehicle groups, indicating that
the 30mg/kg dose of vitexin did not affect the expression of
nicotine sensitization. However, the nicotine–60mg/kg vitexin
group showed a significant decrease in activity compared to the
nicotine–vehicle group. Moreover, there were no differences
between the nicotine–60mg/kg vitexin group and the
Figure 2. Antagonism of the expression of nicotine locomotor expression by
vitexin. Rats were treated once/day for 4 days with 0.4mg/kg nicotine or vehicle
(water). At the end of the habituation phase, each rat was injected with either
the intervention, vitexin or vehicle (DMSO: Tween-80: saline) and their activity
measured for another 30min (middle panel). Immediately following, in the
expression and antagonism phase, each rats was given the challenge dose of
0.4mg/kg nicotine s.c. and their activity recorded for another 60min to assess
sensitization and antagonism by vitexin (bottom panel). Only the first 30min of
the last phase is shown since there was little change in activity in any group
after the first 15min and no significant differences between groups after 10min.
Data shown are mean± SEM for average velocity over each 5-min period.p< 0.01, p< 0.0001 versus vehicle–vehicle–nicotine (control) group, and
xp< 0.05, xxp< 0.01, xxxp< 0.001 versus nicotine–vehicle–vehicle (nicotine-sensi-
tized) group by 2-way ANOVA (time vs. treatment) followed by Tukey’s multiple
comparisons test.
Figure 3. The effect of 60mg/kg vitexin on rat spontaneous activity. Rats were
injected i.p. with either the vehicle (5% DMSO, 5% Tween-80, 90% saline) or
60mg/kg vitexin and were returned to their home cages for 30min before being
placed in the spontaneous activity chambers and their activity recorded for
30min. Data shown are mean±SEM for average velocity over each 5-min period
(n¼ 4 per treatment). No significant differences (p¼ 0.374) were observed by
2-way ANOVA (time versus treatment).
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vehicle–vehicle group (or any group that received the 4-day
vehicle pretreatment). This indicated that the 60mg/kg dose of
vitexin selectively antagonized expression of nicotine
sensitization.
In the second phase of the antagonism experiment (the inter-
vention phase that began with injection of vitexin or vehicle), it
was observed that neither dose had a significant effect on loco-
motion during the 30min prior to the nicotine challenge.
However, habituation results in very low levels of spontaneous
activity, making it difficult to detect more subtle sedative effects.
The final experiment was a control to determine if vitexin had a
sedative effect on locomotor activity on its own during the time
that nicotine was showing locomotor sensitization. Thus, it was
important to test the acute locomotor effects of vitexin under
conditions where the rats had not been habituated to the testing
environment and spontaneous activity was relatively high. The
60mg/kg vitexin dose did not affect locomotion compared to
vehicle in this experiment either. This indicates that the lower
levels of locomotion observed in the antagonism of the expres-
sion of nicotine locomotor sensitization experiment (5–10min
after nicotine and 35–40min after vitexin administration) were
not caused by an acute sedative effect of vitexin. These data sup-
port the conclusion that the effect of 60mg/kg vitexin represents
specific antagonism of the expression of nicotine locomotor
sensitization.
Conclusions
Previous work has demonstrated that a commercial extract of
passion flower antagonized the expression of nicotine locomotor
sensitization in rats (Breivogel and Jamerson 2012). The results
from this study suggest that vitexin is an active ingredient in
passion flower responsible for its effect on nicotine locomotor
sensitization, but does not rule out the possibility that other
compounds in passion flower contribute to this effect or have a
similar effect. The medication varenicline was validated as a
potential drug for smoking cessation using this same
protocol including the strain of rats (Zaniewska et al. 2008).
Following subsequent clinical trials, varenicline was approved
based on demonstrated increases in the chances of quitting
tobacco smoking (Gonzales et al. 2006). Therefore, vitexin shows
potential as a new pharmacotherapy to aid in smoking cessation.
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